<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474654</url>
  </required_header>
  <id_info>
    <org_study_id>15-009</org_study_id>
    <nct_id>NCT02474654</nct_id>
  </id_info>
  <brief_title>Implementation of a Pain Management Protocol for Total Knee Arthroplasty</brief_title>
  <official_title>An Analysis of the Functional Benefit, Narcotic Use and Time to Discharge Readiness Following the Implementation of a Comprehensive Pain Management Protocol for Primary Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Sciences North Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Sciences North Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study question: Is there an ideal combination of intraoperative long acting analgesics&#xD;
      (periarticular infiltration (PI), femoral nerve block (FB) and intrathecal opioids (IO)) to&#xD;
      optimize post-operative functional recovery, decrease overall narcotic consumption and enable&#xD;
      faster 'readiness to discharge' for patients undergoing primary total knee replacement (TKR)?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study design is a five-arm double blinded randomized control trial. In order to create a&#xD;
      blinded study, each participant will have all three interventions (Femoral Nerve Block (FB),&#xD;
      Periarticular Injection (PI) and Intrathecal Opioid (IO)) performed during their visit.&#xD;
      Normal saline (NS) will be substituted for opioid or local anesthetic in cases where a&#xD;
      control is required.&#xD;
&#xD;
      Specific 5 arms include:&#xD;
&#xD;
        -  Using all three anesthetics:&#xD;
&#xD;
           o PI + FB + IO (arm 1)&#xD;
&#xD;
        -  Using a combination of two anesthetics + normal saline substitute for control:&#xD;
&#xD;
             -  NS + FB + IO (arm 2)&#xD;
&#xD;
             -  PI + NS + IO (arm 3)&#xD;
&#xD;
             -  PI + FB + NS (arm 4)&#xD;
&#xD;
        -  Control:&#xD;
&#xD;
             -  NS + NS + IO (arm 5)&#xD;
&#xD;
      The control arm would include IO as the sole intervention as this is simply added to the&#xD;
      spinal anesthetic used for the surgery itself. It is felt that having a study arm without any&#xD;
      long-acting analgesic medication (opioid or local anesthetic) as the &quot;control&quot; arm following&#xD;
      a spinal anesthetic would not meet current standard of care and cause harm to the participant&#xD;
&#xD;
      The investigators hypothesize that the combination of three forms of long acting analgesia&#xD;
      (PI, FB, IO) will result in the greatest outcomes compared to a combination of any two or&#xD;
      control. Our aim is to demonstrate that this optimal analgesic combination will have an&#xD;
      additive pain control effect and will minimize side effects thus translating to less acute&#xD;
      pain, improve patient mobility, and attaining &quot;readiness to discharge&quot; quicker.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">January 14, 2019</completion_date>
  <primary_completion_date type="Actual">January 14, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Discharge</measure>
    <time_frame>Post-op day 1 to discharge date or day 5</time_frame>
    <description>Meeting discharge criteria - Participants will be followed for the duration of hospital stay, approximately 3-5 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time up and go performance measures</measure>
    <time_frame>Post-op day1 to discharge date or day 5</time_frame>
    <description>Measured by physiotherapists - Functional Outcome - Participants will be followed for the duration of hospital stay, approximately 3-5 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Consumption Measures</measure>
    <time_frame>Post-op day 0 to discharge date or day 5</time_frame>
    <description>Narcotic Use and Assessment - Participants will be followed for the duration of hospital stay, approximately 3-5 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Post-op day 0 to discharge date or day 5</time_frame>
    <description>To include nausea, vomiting, pruritis as assessed by Common Terminology Criteria for Adverse Events (CTCAE) - Participants will be followed for the duration of hospital stay, approximately 3-5 days</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Knee Replacement, Total</condition>
  <arm_group>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with1:400,000 Epinephrine 30ml, Normal Saline 100ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivicaine 15mg, Fentanyl 15mcg, Normal Saline 0.3ml, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Normal Saline 100ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivicaine</intervention_name>
    <description>15mg</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>15mcg</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epimorphine</intervention_name>
    <description>150mcg</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.3 ml</description>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>30ml</description>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>100 ml</description>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_label>Arm 5:NS+NS+IO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivicaine</intervention_name>
    <description>100 ml</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>600 mcg</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>30 mg</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 3: PI+NS+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivicaine with Epinephrine</intervention_name>
    <description>0.5% 1:400,000 30ml</description>
    <arm_group_label>Arm 1: PI+FNB+IO</arm_group_label>
    <arm_group_label>Arm 2:NS+FNB+IO</arm_group_label>
    <arm_group_label>Arm 4: PI+FNB+NS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  primary total knee replacement for osteoarthritis&#xD;
&#xD;
          -  agrees to a spinal anesthetic for TKR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of chronic pain or opioid tolerance (individuals requiring equivalent of 1 mg&#xD;
             or more intravenous or 3 mg or more oral morphine per hour for greater than 1 month)&#xD;
&#xD;
          -  general anesthetic for TKR&#xD;
&#xD;
          -  major neurological deficit&#xD;
&#xD;
          -  allergy to local anesthetic&#xD;
&#xD;
          -  allergy to morphine or hydromorphone, anti-inflammatory, acetaminophen&#xD;
&#xD;
          -  renal insufficiency&#xD;
&#xD;
          -  liver failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Wong, MD, FRCPC, BSc, PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Sciences North</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Sciences North Research Institute</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

